Clinical trials: Bladder
Stage III Breast Cancer, Stage IV Breast Cancer
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using…
- Conditions
- Stage III Breast Cancer, Stage IV Breast Cancer, Stage III Lung Cancer, Stage IV Lung Cancer
- Trial name
- NCT04985357
- Sponsor
- Travera Inc
Bladder Cancer
Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer
This is an international, multicenter, double-blind, placebo-controlled, randomized study. All eligible patients entering the open label phase of the study will receive a single immediate instillation of apaziquone (4 mg in 40 mL…
- Trial name
- NCT01410565
- Testing
- Apaziquone
- Where
- 47 sites in United States, Canada
- Volunteers
- 66 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Urinary Incontinence
A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive Bladder
The main aim of the study is to investigate whether taking Tolterodine for overactive bladder symptoms can reduce the thickness of the bladder wall, as measured by intra-vaginal ultrasound.
- Trial name
- NCT00137397
- Testing
- Tolterodine ER
- Where
- 11 sites in United Kingdom
- Volunteers
- 80 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Lower Urinary Tract Symptoms, Overactive Bladder
Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms
The objective of this study is to evaluate the clinical efficacy and safety of tamsulosin alone or in combination with solifenacin for the treatment in men with lower urinary tract symptoms (LUTS) including overactive bladder…
- Conditions
- Lower Urinary Tract Symptoms, Overactive Bladder, Benign Prostatic Hyperplasia (BPH)
- Trial name
- NCT02715024
- Testing
- Tamsulosin, Solifenacin
- Where
- Taiwan
- Volunteers
- 52 people
- Sponsor
- Astellas Pharma Taiwan, Inc.
Urinary Incontinence, Over Active Bladder
Sacral Neuromodulation With InterStim® Therapy for Intractable Urinary Voiding Dysfunctions (SOUNDS): an Observational Study
The purpose of this study is to document the safety, the effectiveness, the continued performance at mid and long term, the morbidity and the percent of surgical revisions of the Interstim® therapy for up to 5 years in a…
- Conditions
- Urinary Incontinence, Over Active Bladder, Urinary Retention
- Trial name
- SOUNDS (NCT02186041)
- Testing
- Sacral Nerve Modulation
- Where
- 24 sites in France
- Volunteers
- 320 people
- Sponsor
- MedtronicNeuro
Overactive Bladder With Urge Urinary Incontinence
URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence
This study will evaluate the efficacy, safety, and tolerability of a single dose of URO-902 24 milligrams (mg) and 48 mg (administered via intradetrusor injection), compared with placebo, in participants with overactive bladder…
- Trial name
- NCT04211831
- Testing
- URO-902
- Where
- 20 sites in United States
- Volunteers
- 80 people
- Sponsor
- Urovant Sciences GmbH
Pelvic Pain, Interstitial Cystitis
Study of U101 for Bladder Pain and/or Urgency
The purpose of this study is to determine whether intravesical U101 (alkalinized lidocaine-heparin) treatment reduces the symptoms of pelvic pain and/or urgency of bladder origin.
- Conditions
- Pelvic Pain, Interstitial Cystitis, Bladder Diseases
- Trial name
- NCT00256542
- Testing
- Alkalinized Lidocaine-Heparin
- Where
- 9 sites in United States
- Volunteers
- 90 people
- Sponsor
- Urigen
Benign Prostatic Hyperplasia, Benign Prostatic Hypertrophy
Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia
To evaluate the efficacy and safety of solifenacin succinate as add-on therapy for overactive bladder (OAB) symptoms in men who have been treated for benign prostatic hyperplasia (BPH) with tamsulosin hydrochloride for at least 6…
- Conditions
- Benign Prostatic Hyperplasia, Benign Prostatic Hypertrophy, Overactive Bladder
- Trial name
- NCT00771394
- Testing
- Tamsulosin hydrochloride, Solifenacin succinate
- Where
- 8 sites in Japan
- Volunteers
- 638 people
- Sponsor
- Astellas Pharma Inc
Cystocele, Rectocele
Clinical Performance of the GYNECARE PROLIFT + M* Pelvic Floor Repair System as a Device for Pelvic Organ Prolapse
The purpose of this study is to evaluate the clinical performance of the PROLIFT system with a new lighter-weight mesh in repair of vaginal prolapse.
- Conditions
- Cystocele, Rectocele, Enterocele
- Trial name
- NCT00833001
- Testing
- GYNECARE PROLIFT+M* Pelvic Floor Repair System
- Where
- 8 sites in Belgium, France and 2 more
- Volunteers
- 126 people
- Sponsor
- Ethicon, Inc.
Interstitial Cystitis
A Study to Test if Fremanezumab Reduces Pain in Patients With Interstitial Cystitis-Bladder Pain Syndrome
The primary objective of the study is to evaluate the efficacy of fremanezumab in reducing pain in patients with interstitial cystitis-bladder pain syndrome (IC-BPS).
- Trial name
- NCT04447729
- Testing
- fremanezumab
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Urinary Tract Infections
Comparison of Pre-procedural PCR and Culture-based UTI Assessment Prior to Intravesical Botox Injection
This study is a retrospective record review to determine whether a novel multiplex PCR assay can be utilized as a screening method for UTI in patients receiving Botox injection to treat overactive bladder (OAB).
- Trial name
- NCT04817865
- Testing
- Multiplex-PCR with Pooled Antibiotic Susceptibility Testing (M-PCR/P-AST), Urine Culture
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pathnostics
Overactive Bladder Syndrome
A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.
This study will assess the efficacy of a 12-week treatment with darifenacin in increasing warning time, the time from first sensation of urgency to voiding, in patients with OAB.
- Trial name
- NCT00171145
- Testing
- Darifenacin
- Where
- United States
- Volunteers
- 445 people
- Sponsor
- Novartis
Bladder Cancer
Longer-term Recurrence Rates in Patients With Bladder Cancer After Hexvix (Cysview)Fluorescence Cystoscopy/TURB
The study is intended to investigate whether the improved initial detection and resection of bladder cancer lesions in patients with non-muscle invasive bladder cancer with Hexvix (Cysview) fluorescence cystoscopy/TURB will lead…
- Trial name
- NCT01166230
- Where
- 24 sites in United States, Austria and 3 more
- Volunteers
- 551 people
- Sponsor
- Photocure
Bladder Neoplasms
Instillation of Gemcitabine in Patients With Superficial Bladder Cancer
A randomized, double-blind, placebo-controlled Phase 3 multicenter study to assess the efficacy and safety of intravesical instillation of gemcitabine versus placebo immediately after transurethral resection of the bladder tumor.
- Trial name
- NCT00191477
- Testing
- Gemcitabine
- Where
- Germany
- Volunteers
- 355 people
- Sponsor
- Eli Lilly and Company
Urothelial Carcinoma
KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer
This is a two-part (dose-escalation, dose-expansion), multicenter, open-label Phase 1 study of KHK2455 in combination with avelumab in adult subjects with locally advanced or metastatic urothelial carcinoma (including bladder…
- Trial name
- NCT03915405
- Testing
- KHK2455, Avelumab
- Where
- 9 sites in United States, Spain
- Volunteers
- 16 people
- Sponsor
- Kyowa Kirin, Inc.
Bladder Neck Obstruction, Benign Prostate Hyperplasia
Assessing Safety & Efficacy of MediTate Temporary Implant in Subjects With Benign Prostate Hyperplasia
The purpose of this study is to assess the safety and efficacy of MediTate Temporary Implantable Nitinol Device (TIND) used to alleviate symptoms of Bladder Outlet Obstruction (BOO) secondary to Benign Prostate Hyperplasia…
- Trial name
- NCT01436877
- Testing
- Insertion of Temporary Implantable Nitinol Device (TIND)
- Where
- Israel
- Volunteers
- 32 people
- Sponsor
- Medi-Tate Ltd.
Urinary Bladder, Overactive
A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder.
The drug being studied, fesoterodine fumarate helps prevent the bladder neck opening at unwanted times and has been shown to help patients with overactive bladder syndrome pass urine less frequently than before treatment.
- Trial name
- SOFIA (NCT00798434)
- Testing
- Fesoterodine fumarate
- Where
- 60 sites in Austria, Belgium and 13 more
- Volunteers
- 794 people
- Sponsor
- Pfizer
Overactive Bladder Syndrome (OABS)
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
SMP-986 is a compound being developed for the treatment of overactive bladder syndrome (OABS). This clinical study is designed to test the hypothesis that SMP-986 at doses of 20mg, 40mg, 80mg or 120mg provides greater symptom…
- Trial name
- NCT00409539
- Testing
- SMP-986
- Where
- 69 sites in United States, Estonia and 7 more
- Volunteers
- 550 people
- Sponsor
- Sumitomo Pharma America, Inc.
Urothelial Carcinoma
HER2 and LA/mUC: A Multi-country Chart Review Cohort Study
This study is being done to learn about urothelial cancers that make HER2 and how that affects treatment choices for participants with urothelial cancer.
- Trial name
- NCT05902494
- Where
- 23 sites in United States, Austria and 2 more
- Volunteers
- 389 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Urinary Incontinence
Detectability of the Bladder With an Early Prototype of the Bladder Sensor
This is an explorative, monocentric, feasibility study to evaluate the detectability of the bladder in healthy subjects by ultrasound monitoring with the early prototype of a future bladder sensor, which is intended for use for…
- Trial name
- NCT04720222
- Testing
- TENA-PROTO1
- Where
- Netherlands
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Essity Hygiene and Health AB
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.